...
首页> 外文期刊>Trends in pharmacological sciences >Does the noncompetitive NMDA receptor antagonist dizocilpine (MK801) really block behavioural sensitization associated with repeated drug administration? (see comments)
【24h】

Does the noncompetitive NMDA receptor antagonist dizocilpine (MK801) really block behavioural sensitization associated with repeated drug administration? (see comments)

机译:非竞争性NMDA受体拮抗剂地佐西平(MK801)是否真的阻止了与重复给药相关的行为敏化? (看评论)

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

The term 'behavioural sensitization' refers to the progressively augmented behavioural response that is produced by many drugs of abuse upon their repeated administration. From most of the available data, it has been concluded that co-administration of an N-methyl-D-aspartate (NMDA) receptor antagonist [such as dizocilpine (MK801)] together with the sensitizing drug can block the development of behavioural sensitization. However, the picture might not be that simple. Recent experimental evidence suggests that instead of blocking sensitization, co-administration of dizocilpine enhances the effect of the the sensitizing drug or has more complex effects on the development of sensitization. In this article, Thomas Tzschentke and Werner Schmidt present these two different views and emphasize that the conclusions that can be drawn from sensitization experiments about the effects of dizocilpine and related drugs on behavioural plasticity crucially depend on how, when and under what conditions a test for sensitization is conducted.
机译:术语“行为敏化”是指许多滥用药物在重复给药后所产生的逐渐增强的行为反应。从大多数可用数据中得出的结论是,N-甲基-D-天冬氨酸盐(NMDA)受体拮抗剂[例如地佐西平(MK801)]与敏化药物共同给药可以阻止行为敏化的发展。但是,情况可能并非如此简单。最近的实验证据表明,与地佐西平合用可以增强敏化药物的作用,或者对敏化的发展具有更复杂的作用,而不是阻断敏化作用。在本文中,Thomas Tzschentke和Werner Schmidt提出了两种不同的观点,并强调从敏化性实验中得出的关于地佐西平和相关药物对行为可塑性的影响的结论主要取决于测试的方式,时间和条件。进行敏化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号